
Loading, please wait...

Loading, please wait...

Heart failure treatment costs in India represent a critical barrier to effective long-term disease management. A recent nationwide study published in the journal Global Heart found that 70% of patients lack any financial protection. Consequently, families pay for almost all medical expenses from their personal savings. This growing economic burden often leads to medication non-adherence and poor health outcomes.
The research analyzed 1,859 patients across 21 tertiary hospitals between 2019 and 2022. It highlighted that patients bear over 90% of their healthcare costs directly. On average, an individual spends more than ₹1 lakh annually on treatment. Because incomes often drop after a diagnosis, these expenses quickly become unsustainable. Nearly 38% of households face catastrophic spending, leading to severe financial distress and asset liquidation.
Current insurance schemes like Ayushman Bharat primarily focus on hospitalization and acute procedures. However, heart failure is a chronic condition that requires consistent outpatient care. This includes regular follow-ups, diagnostic tests, and expensive lifelong medications. Therefore, even patients with some coverage still face high out-of-pocket bills. Furthermore, many families must borrow money or sell assets just to survive.
Clinicians emphasize that financial strain directly impacts clinical care. Doctors frequently adjust treatment plans based on what a patient can afford. As a result, patients may skip essential drugs or delay necessary check-ups. Consequently, the lack of structured financial support for outpatient services remains a major gap. Expanding insurance to cover long-term pharmacy costs is essential for patient survival.
Q1: Why are heart failure treatment costs so high in India?
Costs are high because the disease requires lifelong medication and repeated hospital visits. Most insurance plans only cover inpatient stays, leaving patients to pay for daily drugs out of pocket.
Q2: How does financial burden affect clinical outcomes?
Economic pressure leads patients to cut doses or delay follow-up tests. This results in worsening heart function and more frequent, expensive emergency hospitalizations.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A recent study shows 7 in 10 heart failure patients in India lack insurance, with 90% of treatment costs paid out-of-pocket, leading to financial distress....
5 months ago

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today

In high-risk pulmonary embolism complicated by severe anemia and active uterine bleeding, systemic thrombolysis is contraindicated. Large-bore aspiration thrombectomy provides rapid hemodynamic rescue without fibrinolysis, supported by inferior vena cava filter placement and multidisciplinary critical care.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today